| Field | Specification |
|---|---|
| Target | |
| CAS no. | |
| Applications | |
| Molecular weight | |
| Molecular formula | C55H87N15O22 |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Compound Overview
CXJ-2 is a cyclic peptide that shows moderate affinity for elastin-derived peptides (EDPs). It potently inhibits the PI3K/ERK pathway and decreases hepatic stellate cell proliferation and migration, and it possesses potent antifibrotic efficacy[1]. It has the molecular formula C55H87N15O22 (MW 1310.37) and the sequence cyclo(Val-{Iva}-Gly-Ser-Pro-Ser-Ala-Gln-Glu-Glu-Ala-Ser-Pro-Ala).
Physical & Chemical Properties
| CAS Number | 2919976-92-2 |
|---|---|
| Molecular Formula | C55H87N15O22 |
| Molecular Weight | 1310.37 g/mol |
| Sequence | cyclo(Val-{Iva}-Gly-Ser-Pro-Ser-Ala-Gln-Glu-Glu-Ala-Ser-Pro-Ala) |
| Sequence (one-letter) | cyclo(V-{Iva}-GSPSAQEEASPA) |
| Target | PI3K, ERK |
| Signaling Pathway | PI3K/Akt/mTOR; Stem Cell/Wnt; MAPK/ERK Pathway |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Shipping | Room temperature in continental US; may vary elsewhere. |
Literature Cited
Sources cited in this description and in the In Vitro & In Vivo Data tab. Peer-reviewed publications that used this product are listed under References.
Safety
For Research Use Only. Not for use in diagnostic or therapeutic procedures, and not for human or veterinary use. Handle in accordance with your institution's chemical hygiene plan.
In Vitro
In LX2 cells, CXJ-2 (10 μM, 24 h) reduces α-SMA expression in a dose-dependent manner[1]. CXJ-2 (10 μM, 24 h) shows superior activity in inhibiting LX2 cell proliferation[1].
In Vivo
In mice, CXJ-2 (150 μg/kg, IP, daily for 3 weeks) markedly diminishes hepatic fibrosis[1]. CXJ-2 (0.1 mg/kg, SC, single dose) displays favorable pharmacokinetic properties[1].
| Animal Model | Male C57BL/6J mice (6-8 weeks, 20-24 g, CCl4-induced liver fibrosis model)[1] |
|---|---|
| Dosage | 150 μg/kg |
| Administration | IP, daily, for 3 weeks |
| Result | Significantly decreased the HYP (hydroxyproline) content in liver tissue. Decreased collagen deposition. Remarkably diminished hepatic fibrosis. |
| Animal Model | Sprague-Dawley rats[1] |
|---|---|
| Dosage | 0.1 mg/kg |
| Administration | SC, single dose (Pharmacokinetic Analysis) |
| Result | Showed favorable pharmacokinetic properties (Tmax=0.33 h, T1/2=0.46 h), and displayed enhanced clearance profiles. Displayed significantly higher serum stability with a half-life longer than 36 h. |
Data provided by the manufacturer. Numbered citations refer to the Literature Cited list in the product description.
Need this compound in a format that drops straight into your assay? We can tailor formulation, chemistry, and documentation so your results stay consistent across runs and re-orders.
- Format options: solid or pre-dissolved solution (choose solvent), target concentration, aliquots, light/moisture-protected packaging
- Chemistry options: free base/acid vs salt forms, hydrate/solvate preference, stereoisomer control (single enantiomer or racemate), close analogs
- Add-on labels & handles: D/¹³C/¹⁵N isotopes (LC-MS/internal standards), azide/alkyne or other functional handles for conjugation
- QC & documentation: standard COA or enhanced analytical pack (HPLC/LC-MS/NMR), chiral purity, residual solvents, water content (KF), method-specific specs
- Scale & continuity: mg to gram scale, bulk pricing, lot reservation, repeat-order continuity
To quote quickly, tell us: compound name + CAS/structure (SMILES or mol file), intended assay context, solvent preference, salt/stereochemistry requirements, purity/QC level, and the amount (mg–g).
Can’t find the compound you’re looking for?
Send the CAS or structure and your specs. We can help source it, suggest close equivalents, or discuss custom synthesis with the right QC documentation (RUO).
